Abstract:Diabetic nephropathy (DN) is a common and serious microvascular complication of diabetes mellitus (DM). According to epidemiological studies, more than 425 million people worldwide are currently affected by diabetes. If no action is taken, more and more people with diabetes worldwide will rise to 629 million by 2045. [ 1 ] As the prevalence of diabetes has increased, the incidence of DN has increased rapidly. Being expected to 30% to 40% of diabetic patients develop DN, finally, the one third of DN patients develop end-stage renal disease. Currently, it has been shown that the mechanism of DN is the result of a combination of factors such as glucose metabolism disorders, changes in glomerular hemodynamics, inflammatory reactions, cytokines, endothelial damage, oxidative stress, ischemia and hypoxia, and genetic susceptibility. Chronic renal hypoxia, caused by various factors such as hyperglycemia, endothelial damage, and inflammatory responses, is one of the main causes of the occurrence and development of DN. Hypoxia is considered as an etiological factor in the progression of renal injury. HIF1α is a major transcription factor that transduces an array of cellular processes to let the cells adapt to hypoxic injury. Therefore, a sustained increase in HIF1α is a major adaptive stimulus to the hypoxic conditions. [ 2 ] By regulating its target ZEB2 gene (Zinc finger E-box-binding homeobox 2), it affects pathological and physiological processes such as glucose, energy metabolism, inflammation, and plays an essential role in the occurrence and development of DN. [ 3–5 ] There is a growing body of evidence that hypoxia can cause kidney damage, inflammatory reactions, loss of podocytes and abnormal function, and reduced glomerular filtration rates leading to proteinuria. If not intervened in a timely manner at an early stage, this is a huge financial burden on society. [ 6 ] Western medications are used to treat DN by regulating blood glucose, blood lipid levels and blood pressure. Early medical studies have shown that angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (angiotensin II receptor blockers) as first-line treatment for DN can reduce proteinuria, The role of delaying the progress of renal dysfunction. [ 7 ] However, the side effects of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers limit the use of these drugs. Therefore, the search for safe and effective therapies for DN is of great urgency.

Hypertensive Nephropathy Changes the Expression of Drug-Metabolizing Enzymes and Transporters in Spontaneously Hypertensive Rat Liver and Kidney

Comparative Analysis Of Renal Protein Expression In Spontaneously Hypertensive Rat

Renal Biomarker Changes Associated with Hyaline Droplet Nephropathy in Rats Are Time and Potentially Compound Dependent.

Epigenetics of Hypertensive Nephropathy

TNF-? and IL-1? Promote Renal Podocyte Injury in T2DM Rats by Decreasing Glomerular VEGF/eNOS Expression Levels and Altering Hemodynamic Parameters

Single-nucleus Sequencing Reveals Endothelial Cell-specific Dysregulation in the Kidney in Multiple Models of Hypertension

The Renal L-arginine/nitric Oxide Pathway and Erythrocyte L-arginine Transport in Spontaneously Hypertensive Rats

Exploring the mechanism of Dahuang-Tusizi drug pair in the treatment of diabetes nephropathy based on network pharmacology and immune infiltration analysis

Non-alcoholic fatty liver disease changes the expression and activity of hepatic drug-metabolizing enzymes and transporters in rats

Huperzine A as a potential therapeutic drug for diabetic nephropathy: Insights from transcriptome, metabolome, microbiome, and network pharmacology analysis

Single-cell transcriptome sequencing reveals molecular mechanisms of renal injury in essential hypertension

Nuclear receptors in renal health and disease

WHAT IS THE MAJOR FACTOR ON THE KIDNEY INJURY INDUCED BY HYPERTENSION OR HYPERHOMOCYSTEINEMIA

Glomerular 20-HETE, EETs, and TGF-beta1 in diabetic nephropathy

Genetic Susceptibility of Hypertension‐induced Kidney Disease

Hypercholesterolemia reduces the expression and function of hepatic drug metabolizing enzymes and transporters in rats

Network pharmacology combined with Mendelian randomization analysis to identify the key targets of renin-angiotensin-aldosterone system inhibitors in the treatment of diabetic nephropathy

Key Players in Hypertensive Renovascular Damage

Advances in the pharmacological study of Chinese herbal medicine to alleviate diabetic nephropathy by improving mitochondrial oxidative stress

Huayu Tongluo Recipe Attenuates Renal Oxidative Stress and Inflammation through the Activation of AMPK/Nrf2 Signaling Pathway in Streptozotocin- (STZ-) Induced Diabetic Rats

Diabetic Nephropathy: Focusing on Pathological Signals, Clinical Treatment, and Dietary Regulation.